Intravenous-to-Subcutaneous Drug Markets
|出版商||Greystone Research Associates||商品編碼||366042|
|IV-to-SC轉用藥 (從靜脈給藥到皮下注射治療的轉用藥)的市場 Intravenous-to-Subcutaneous Drug Markets|
|出版日期: 2016年08月09日||內容資訊: 英文||
The number of drugs based on biologicals continues to grow at an increasingly rapid rate. Because of their physical properties and the relatively high administration volumes often required to achieve the desired therapeutic effect, the majority are developed and launched for intravenous administration. This is creating a burgeoning demand for infusion facilities, personnel and equipment. The relative complexity, costs and patient logistics associated with IV infusion relative to other routes of administration is creating interest in post-launch re-engineering of IV drugs to allow them to be administered subcutaneously. A number of technology approaches are currently being employed to accomplish this migration. By pursuing intravenous-to-subcutaneous drug markets, drug owners are finding they can achieve a number of competitive advantages.